Dicerna Pharmaceuticals Inc represents values of innovation, scientific excellence, and patient-centricity. The company is committed to advancing RNA interference (RNAi) technology to develop transformative therapies. By leveraging its GalXC™ platform, Dicerna aims to deliver targeted and durable treatments for patients with unmet medical needs. With a focus on precision medicine, Dicerna values collaboration, integrity, and social responsibility. By prioritizing patient well-being, Dicerna Pharmaceuticals Inc strives to make a significant impact on human health by developing breakthrough therapies that address the underlying causes of diseases.

Dicerna Pharmaceuticals Inc is primarily present in the United States. As a biopharmaceutical company, Dicerna focuses on the development of innovative RNA interference (RNAi) therapeutics. With headquarters located in Lexington, Massachusetts, Dicerna operates primarily within the United States.

Dicerna Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and commercialized RNA interference (RNAi) therapies, demonstrating their expertise in the field. In 2018, Dicerna received approval from the U.S. Food and Drug Administration for their lead product, Patisiran, for the treatment of patients with rare hereditary transthyretin amyloidosis (hATTR). Dicerna also expanded its pipeline with promising preclinical and clinical programs targeting a wide range of diseases, including liver, cardiovascular, and viral diseases. Moreover, the company established strategic collaborations with renowned pharmaceutical companies to further enhance their research and development capabilities. These achievements highlight Dicerna Pharmaceuticals Inc's dedication to advancing innovative therapies and addressing unmet medical needs.

Dicerna Pharmaceuticals Inc. is a leading biopharmaceutical company specializing in the discovery and development of RNA interference (RNAi) therapeutics. Founded in 2007, Dicerna aims to harness the power of RNAi to create targeted therapeutics for patients with rare diseases and disorders. The company's innovative platform enables the design and optimization of potent RNAi molecules that can selectively silence disease-causing genes. Dicerna's commitment to scientific excellence and strategic partnerships has led to significant advancements in RNAi therapeutics, making them a recognized leader in the field. With a focus on addressing unmet medical needs, Dicerna Pharmaceuticals Inc. continues to pave the way for cutting-edge treatments using RNAi technology.

Dicerna Pharmaceuticals Inc faces competition from various companies in the market. Some of its main competitors include Alnylam Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc. These companies also specialize in developing RNA interference (RNAi) therapeutics and share a similar focus on innovative treatments for various diseases. However, Dicerna Pharmaceuticals Inc distinguishes itself through its proprietary RNAi technology platform and its pipeline of potential therapies targeting unmet medical needs.

Dicerna Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

Dicerna Pharmaceuticals Inc is a biopharmaceutical company that focuses on discovering and developing innovative RNAi-based therapeutics. Their business model revolves around utilizing their proprietary GalXC™ RNAi platform to develop medicines that silence genes causing disease. By harnessing the potential of RNA interference, Dicerna aims to address a variety of diseases with unmet medical needs. With a strong commitment to scientific excellence and collaboration, Dicerna Pharmaceuticals Inc strives to bring transformative treatments to patients while creating value for shareholders.

Το Dicerna Pharmaceuticals P/E είναι -19,00.

Το KUV της εταιρείας Dicerna Pharmaceuticals είναι 16,59.

Το AlleAktien Qualitätsscore για το Dicerna Pharmaceuticals είναι 4/10.

Ο κύκλος εργασιών του αναμενόμενη Dicerna Pharmaceuticals είναι 170,98 Εκ. USD.

Το αναμενόμενη Dicerna Pharmaceuticals κέρδος είναι -149,22 Εκ. USD.

Dicerna Pharmaceuticals Inc is a publicly traded biopharmaceutical company based in Lexington, Massachusetts, specializing in RNAi technology (RNA interference). The company was founded in 2007 and currently employs around 150 employees.

Η Dicerna Pharmaceuticals καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Dicerna Pharmaceuticals αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Dicerna Pharmaceuticals είναι US2530311081.

Το WKN της Dicerna Pharmaceuticals είναι A1XCYU.

Ο τίκερ της Dicerna Pharmaceuticals είναι DRNA.

Κατά τους τελευταίους 12 μήνες η Dicerna Pharmaceuticals κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Dicerna Pharmaceuticals προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Dicerna Pharmaceuticals ανέρχεται σήμερα στο .

Dicerna Pharmaceuticals πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Dicerna Pharmaceuticals πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Dicerna Pharmaceuticals ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Dicerna Pharmaceuticals από την 7/7/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 7/7/2024.

Η τελευταία μερίσματος έγινε στις 7/7/2024.

Το έτος 2023, η Dicerna Pharmaceuticals διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Dicerna Pharmaceuticals καταβάλλονται σε USD.